Veraspir Diskus

Selected form

Method of action: Antiallergic, Anti-Asthmatic, Anti-Inflammatory, Beta-Adrenomimetic, Bronchodilator, Drugs For Obstructive Airway Diseases, Glucocorticoid

Treatment option: Asthma

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Veraspir Diskus

Quick Facts about Veraspir Diskus

Property	Description
Active Ingredients	Fluticasone Propionate & Salmeterol Xinafoate
Form	Dry Powder Inhaler (DPI)
Pharmacological Class	Inhaled Corticosteroid (ICS) / Long-Acting Beta-Agonist (LABA) Combination
Status	Prescription-Only (Rx)
Delivery System	Breath-Activated Diskus Device

What Type of Medicine is Veraspir Diskus?

Veraspir Diskus is a prescription-only combination inhaled medicine that provides long-term, maintenance treatment for chronic airway diseases. It belongs to the fixed-dose combination drug class known as an Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA).

This specific combination delivers two distinct therapeutic effects—anti-inflammation and sustained bronchodilation—in a single device. The goal of this dual approach is to achieve superior, sustained disease control compared to using a single agent. This medication is used when symptoms are not controlled sufficiently on other medications or when more than one daily medicine is required.

What Is It Made Of and How Is It Delivered?

The medicine contained within Veraspir Diskus is a fine, dry powder formulation containing the active synthetic ingredients Fluticasone Propionate and Salmeterol Xinafoate. Fluticasone is the anti-inflammatory component, while Salmeterol is the long-acting relaxant for airway muscles.

The medication is administered via the Diskus device, a type of Dry Powder Inhaler (DPI). This delivery system is specifically breath-activated, meaning the medicine is dispersed when the patient takes a deep, fast breath. This design eliminates the complex hand-breath coordination required for some older inhaler types and incorporates a dose counter, which is a key feature for consistent adherence to therapy.

What is the General Purpose of This Combination Drug?

The general purpose of Veraspir Diskus is to sustain open airways and reduce internal inflammation to help prevent future breathing problems. The corticosteroid component reduces the underlying swelling inside the airways, while the long-acting beta-agonist component keeps the airway muscles relaxed for approximately 12 hours. This sustained, preventative effort improves lung function and symptoms in patients with persistent asthma. This medicine is always used for daily control and should not be relied upon for rapid relief during an acute breathing attack.

Regulatory References

What side effects are possible with Veraspir Diskus?

Official Safety Profile and Adverse Reactions

The safety profile for Veraspir Diskus is structured by regulatory documents, which classify potential adverse reactions based on body systems affected and their frequency of occurrence in clinical use.

Frequency-Classified Adverse Reactions

The official Summary of Product Characteristics (SmPC) and FDA labeling identify adverse reactions with specific frequency categories.

Classification	Examples of Documented Adverse Reactions
Very Common	Headache, Nasopharyngitis.
Common	Oral candidiasis (thrush), Pharyngitis, Dysphonia (hoarseness), Bronchitis, Tremor, Palpitations.

Adverse reactions are grouped into System-Organ Classes, which include Infections and Infestations (e.g., pneumonia in COPD patients), Nervous System Disorders, Cardiac Disorders, and Metabolism and Nutrition Disorders (e.g., hyperglycemia, hypokalemia). Systemic effects of the corticosteroid component, such as potential adrenal suppression or bone mineral density reduction, are associated with long-term exposure, particularly at higher doses.

Serious Adverse Reactions and Safety Constraints

The regulatory profile documents potential serious adverse reactions, including Paradoxical Bronchospasm, which necessitates immediate discontinuation of the medicine. The Salmeterol component carries the documented LABA-related risk of serious asthma-related events.

Population and Use Constraints

Safety statements specify that the medicine is contraindicated for treating acute episodes of asthma or COPD. Specific population considerations exist, such as the requirement for growth monitoring in pediatric patients and the need for close monitoring in individuals with severe hepatic impairment, as documented in the official prescribing information.

Overdose and Emergency Response

Overdose manifestations for Veraspir Diskus are primarily linked to the Salmeterol component. Acute excessive exposure may present with signs of excessive beta-adrenergic stimulation, including tachycardia (increased heart rate), tremor, and palpitations. Other documented acute manifestations include headache, nausea, and vomiting. Of serious concern, overdose can lead to profound hypokalaemia (low serum potassium levels), cardiac arrhythmias, and QTc interval prolongation, which are documented as potentially life-threatening outcomes.

The official label mandates that individuals seek immediate medical attention following any suspected overdose, and the medicine must be discontinued. Management is symptomatic and supportive, requiring cardiac monitoring and laboratory monitoring of potassium and glucose levels due to metabolic risks. No specific antidote is known for Salmeterol overdose. While a cardioselective beta-blocking agent may be considered as a supportive measure, regulatory documents advise extreme caution due to the risk of inducing bronchospasm. Long-term, chronic excessive exposure to the Fluticasone component may lead to adrenal suppression or acute adrenal crisis.

Therapeutic Uses of Veraspir Diskus

What Veraspir Diskus Treats: Main Uses and Benefits

Veraspir Diskus is commonly used as a part of a long-term strategy for managing chronic respiratory conditions. It is applied to help control the symptoms of persistent asthma in patients aged 4 years and older, as well as for the management of Chronic Obstructive Pulmonary Disease (COPD). This combination therapy is considered relevant when symptoms are not adequately controlled on a single agent or when the disease warrants dual-agent management.

This sustained treatment may be part of symptomatic management applied across domains where additional support is needed for conditions like chronic bronchitis and emphysema. Its role is commonly used to help with managing persistent symptoms that interfere with daily functioning, such as wheezing, coughing, and chest tightness.

“This medicine plays a role in managing conditions characterized by periods of heightened symptoms.”

Relief of Chronic Wheezing and Airway Obstruction

Veraspir Diskus is applied in addressing symptoms related to inflammatory or irritative states that lead to the persistent tightening of the airways. By assisting with airway stability, it may support patients in maintaining functional stability and contribute to improved comfort during periods of heightened symptoms in adults and children with chronic lung illness. This sustained treatment may assist with managing symptoms that become more disruptive during flare-ups.

Quick Fact: Relief for Respiratory Symptoms
Symptom Management Focus: Persistent wheezing, chronic cough, and chest tightness.
Main Therapeutic Benefit: Contributes to easing the overall symptom load during periods of heightened discomfort.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Veraspir Diskus

Official regulatory guidelines strictly define the population groups approved for, restricted from, or absolutely prohibited from using this medicine.

Category	Official Regulatory Classification/Statement
Populations Allowed	Adults and adolescents aged 12 years and older with asthma not adequately controlled on an inhaled corticosteroid (ICS) alone [FDA Label]. Children aged 4 to 11 years with asthma under the same conditions [FDA Label]. Adult patients for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) [FDA Label].
Absolute Contraindications	Patients with a known severe hypersensitivity to milk proteins (lactose) or any component of the formulation [FDA Label]. Patients presenting for primary treatment of status asthmaticus or other acute respiratory episodes [FDA Label]. Use with an additional medicine containing a Long-Acting Beta-Agonist (LABA) is prohibited [FDA Label].
Conditional Use/Caution	Use requires caution and monitoring in patients with pre-existing cardiovascular disorders (e.g., hypertension, arrhythmias), diabetes mellitus, or untreated systemic infections (e.g., tuberculosis, ocular herpes simplex) [FDA Label]. Patients with hepatic impairment should be monitored for signs of increased systemic exposure [FDA Label].
Age-Related Restrictions	Safety and effectiveness have not been established in children younger than 4 years of age for asthma [FDA Label].
Pregnancy and Lactation	Pregnancy: Use only if the expected benefit justifies the potential risk to the fetus [UK SmPC]. Lactation: Decision required to discontinue nursing or discontinue the medicine as it is unknown if the active ingredients are excreted in human breast milk [FDA Label].

Official documents define eligibility by classifying patient status, emphasizing that use is contraindicated during acute illness or in patients with certain allergies. Use is restricted to those aged 4 years and older who meet specific chronic disease control criteria, and requires caution in patients with specific comorbidities to manage potential risks.

What should I know about interactions with other medicines?

The interaction profile for Veraspir Diskus is structured around pharmacokinetic and pharmacodynamic constraints documented in official regulatory labeling.

Contraindicated and Exposure-Altering Combinations

The use of Veraspir Diskus is contraindicated with other Long-Acting Beta-Agonists (LABAs) due to the severe risk of additive effects on the cardiovascular system. Co-administration is also not recommended with strong Cytochrome P450 3A4 (CYP3A4) inhibitors, such as Ritonavir or Ketoconazole. This is a pharmacokinetic interaction where these medicines inhibit the clearance of both active ingredients, leading to significantly increased systemic exposure. Certain food substances, including grapefruit juice, are similarly identified as strong CYP3A4 inhibitors that may cause this exposure modification.

Pharmacodynamic Interaction Cautions

The medicine requires documented caution when co-administered with other drug classes that affect the cardiovascular or electrolyte systems. Beta-Blockers may antagonize the bronchodilatory action of the Salmeterol component, potentially resulting in bronchospasm. Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) may potentiate cardiovascular effects. Furthermore, the combination with non-potassium-sparing diuretics carries a documented risk of additive effects, which may lead to hypokalemia. For patients with impaired hepatic function, the clearance of the active ingredients may be reduced, increasing the risk of systemic accumulation.

Mechanism of Action

Veraspir Diskus is an inhaled corticosteroid that is absorbed through the airway epithelium. The active moiety binds with high affinity to the glucocorticoid receptor, forming a complex. This complex translocates to the cell nucleus, where it alters the transcription of target genes. This action results in the upregulation of anti-inflammatory proteins and the downregulation of pro-inflammatory cytokines and chemokines, including interleukins and tumor necrosis factor-alpha. The mechanism also involves the inhibition of mast cell degranulation and the modification of inflammatory mediator release from these and other immune cells. The lipophilic properties of the molecule facilitate prolonged tissue retention in the lung.

Dosage and Administration Information

General Administration Principles

Veraspir Diskus (fluticasone propionate/salmeterol) is a long-term maintenance medicine administered exclusively by oral inhalation via the breath-activated Diskus device. The following usage principles apply to its administration.

Standard Dosing and Frequency

Population / Indication	Approved Strengths (FP/SAL mcg)	Standard Frequency
Adults & Adolescents (Asthma)	100/50, 250/50, or 500/50	One inhalation twice daily
Children (4 to 11 years, Asthma)	100/50 only	One inhalation twice daily
Adults (COPD)	250/50 only	One inhalation twice daily

The maximum recommended dosage for any indication is one inhalation of the prescribed strength twice daily, approximately 12 hours apart (morning and evening). The higher strengths (e.g., 500/50 mcg) are not used for COPD, as no clinical advantage has been demonstrated over the 250/50 mcg strength.

Procedural and Administration Rules

Mouth Rinsing: A critical step after each dose is to rinse the mouth with water and spit out the water (do not swallow) to limit local effects of the corticosteroid component.
Acute Use Restriction: Veraspir Diskus is designated only for long-term maintenance and must not be used for the immediate relief of sudden breathing problems or acute bronchospasm. An inhaled short-acting beta2-agonist (SABA) should be used for immediate relief between doses.
Missed Dose: If a dose is missed, it should be skipped. The next dose must be taken at the usual scheduled time, and the dose should not be doubled to compensate.

Recent Clinical Evidence

Veraspir Diskus: Recent Clinical Evidence

Evidence for Use in Persistent Asthma

This section will summarize the structure of the clinical evaluation for persistent asthma, focusing on the Randomized Controlled Trials (RCTs) conducted and the primary outcomes researchers sought to measure, such as changes in lung function and the frequency of exacerbations.

The research exploring this medicine for persistent asthma is primarily based on RCTs. These studies were observed in trials evaluating its use as a long-term, maintenance treatment in adults, adolescents, and children. Research monitored outcomes related to systemic or functional imbalance, such as Forced Expiratory Volume in one second (FEV1), a measure of airway function. Studies also monitored clinical indicators related to cycles of stability and flare-ups, including the number of symptom-free days and measurements related to the frequency of asthma exacerbations and rescue medication use. Research provides insight into short-term changes; however, long-term effects are not fully established, and data for certain groups remain insufficient when considering the medicine's use over many years.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

This part will describe the large-scale multi-year clinical trials and systematic reviews that form the basis of the COPD research, detailing the specific outcomes examined, including hospitalization rates and patient-reported quality of life measures.

The evidence base supporting its use in COPD includes large-scale, multi-year RCTs and systematic reviews primarily evaluating adults with moderate-to-severe airflow limitation. The research examined outcomes related to physical discomfort and functional limitations. Studies monitored clinical event outcomes, focusing on the frequency and severity of COPD exacerbations and COPD-related hospitalizations. Findings describe patterns observed in the studies where participants reported measurements related to the frequency of COPD exacerbations. While evidence contributes to understanding symptom patterns, comparative evidence is lacking regarding direct, head-to-head comparisons across all available fixed-dose inhaler options, and the evidence quality varies across studies.

Research Gaps and Areas of Scientific Uncertainty

The research has explored the effects of the medicine over defined time intervals, with some key clinical outcome trials observing responses over periods of up to three years, supporting its use in maintenance treatment. The research included patient groups defined by disease severity (moderate-to-severe COPD, children/adolescents), but the results apply only to the populations studied. Data for specific comorbidity-defined groups remain insufficient, and certainty remains low in some areas. Research does not determine whether an individual will respond similarly to the group patterns reported.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Veraspir Diskus (FAQ)

Q: When does Veraspir Diskus start working? How fast is the effect?

According to official product information, Veraspir Diskus is a long-term maintenance treatment and is not indicated for the relief of acute breathing problems. The medicine is not designed to work fast enough to stop an asthma attack or sudden episode. Official guidelines indicate a separate, fast-acting rescue inhaler is needed for acute symptoms.

Q: Can I take Veraspir Diskus for an ongoing asthma attack or an emergency?

No, official regulatory documents state that Veraspir Diskus is not a rescue medication. It should never be used for immediate relief during an asthma attack or sudden worsening of breathing. The product labeling specifies that a separate short-acting beta-agonist (SABA) is required for the treatment of acute symptoms.

Q: What should I do if my symptoms worsen after starting Veraspir Diskus?

Official regulatory warnings describe circumstances that require immediate medical attention, such as worsening breathing problems after starting this medicine. Immediate medical review is required if the fast-acting rescue inhaler seems less effective than usual. These circumstances indicate a potential change in a patient's condition that requires urgent medical review.

Q: Does the inhaler make a sound when I take a dose correctly?

Yes, according to the patient instructions for use in the regulatory label, the Diskus inhaler is designed to produce a distinct click. This sound is described as confirming that the dose lever has been fully activated and the medicine is prepared for inhalation.

Q: Is it safe to suddenly stop taking Veraspir Diskus?

Official warnings state that abrupt cessation of the medicine is not recommended and should only occur under the guidance of a prescriber. Sudden discontinuation may lead to a worsening of asthma or COPD symptoms. It may also lead to symptoms of adrenal insufficiency, a condition where the body does not produce enough steroid hormones.

Q: Will Veraspir Diskus make me feel shaky, nervous, or cause insomnia?

Official documents report that the active components may cause certain effects. Adverse reactions documented in clinical trials include nervousness, tremor (feeling shaky), and sleep disorders. These effects are generally related to the long-acting beta-agonist component of the medicine.

Q: Is there a generic version of Veraspir Diskus available?

Yes. Regulatory authorities in various countries have approved generic versions of the combination medication (fluticasone propionate and salmeterol inhalation powder). The availability of a generic may vary based on your location and pharmacy.

Q: Will Veraspir Diskus affect my ability to drive or operate machinery?

Based on the product information, this medicine is generally not expected to impair the ability to drive or use machines. Official documents suggest exercising caution until an individual knows how the medicine affects them.

Q: What are the signs of a severe allergic reaction to this medicine?

Official safety warnings describe that immediate medical attention is necessary if signs of a serious allergic reaction are experienced. These signs include swelling of the face, mouth, or tongue, or the sudden worsening of breathing problems right after using the inhaler.

Q: Is Veraspir Diskus a bronchodilator?

Veraspir Diskus is a combination product containing two different types of medicine. One of the active ingredients, salmeterol, is classified as a long-acting beta2-adrenergic agonist, which functions as a bronchodilator (a medicine that relaxes and opens the airways). The other is an inhaled corticosteroid.

Q: Does it cause agitation or restlessness?

Official regulatory documents list agitation and restlessness as adverse reactions. These effects have been reported as part of post-marketing experience or are classified as uncommon adverse reactions in clinical use.

Q: Is it safe to use Veraspir Diskus long-term?

Long-term use of the inhaled corticosteroid component is associated with certain systemic risks documented in regulatory warnings. These risks include reduced bone mineral density, cataracts, and glaucoma. Official warnings describe that patients using this medicine long-term require close monitoring by a healthcare professional.

Q: Is it safe to use Veraspir Diskus during pregnancy or while breastfeeding?

Regulatory documents state this medicine should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus. Regarding breastfeeding, official information indicates that following therapeutic inhalation, drug concentrations in human breast milk are expected to be low.

How should Veraspir Diskus be stored and disposed of?

How to Store and Dispose of Veraspir Diskus?

The storage and handling of Veraspir Diskus (fluticasone propionate and salmeterol inhalation powder) must strictly follow the conditions defined in official regulatory labeling to ensure product integrity.

Official Storage Requirements

Condition	Requirement (As per Regulatory Labeling)
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F); do not freeze.
Protection	Keep in a dry place, away from direct heat and strong sunlight.
Packaging	Store in the original sealed foil pouch until ready for first use.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The Diskus must be discarded one month (30 days) after the foil pouch is opened or when the dose counter reads ‘0’, whichever comes first. To dispose of unused or expired medicine, consult a pharmacist or local authority for guidance on proper procedures. Regulatory guidelines advise against disposal through household wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Portugal

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z